NEW YORK (360Dx) – Beckman Coulter, a Danaher company, today announced that the US Food and Drug Administration has granted 510(k) clearance for its Early Sepsis Indicator ­— a hematology-based cellular biomarker to help emergency department physicians identify patients that have sepsis or are at increased risk of developing sepsis.